Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Fritsch, P; Schwinger, W; Schwantzer, G; Lackner, H; Sovinz, P; Wendelin, G; Benesch, M; Sipurzynski, S; Urban, C.
Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies.
Pediatr Blood Cancer. 2010; 54(1): 134-137.
Doi: 10.1002/pbc.22304
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Fritsch Peter
- Co-Autor*innen der Med Uni Graz
- Benesch Martin
- Lackner Herwig
- Ritter-Sovinz Petra
- Schwantzer Gerold
- Schwinger Wolfgang
- Sipurzynski Sabine
- Urban Ernst-Christian
- Wendelin Gerald
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background. Pegfilgrastim, the long acting agent of rh-GCSF, has been shown to be as effective as Filgrastim in children undergoing cytotoxic chemotherapy by reducing the duration of neutropenia. Recent studies in adults have also shown that Pegfilgrastim is effective to mobilize CD34+ stem cells, resulting in earlier peripheral stem cell collections (PSCC). The aim of the study was to compare the efficacy of Pegfilgrastim with Filgrastim for CD34+ stem cell mobilization in children. Procedure. Three groups of patients were compared: Group 1: six patients with Ewing Sarcoma stimulated with Filgrastim; Group 2: five patients with Ewing Sarcoma, Ependymoma, and Neuroblastoma; Group 3: four patients with relapsed neoplasm. Patients of Group 2 and 3 were stimulated with Pegfilgrastim followed by peripheral stem cell collection. Two patients in Group 3 needed further cytokine stimulation with Filgrastim combined with stem cell factor, Ancestim. Results. In Groups 1-3, a median of 4, 3, and 3 PSCC between day 12-24, 6-13, and 8-30 were performed, yielding a median of 14.2, 24.0, and 10.3 x 10(6) CD34+ stem cells/kg BW, respectively. Conclusions. Group 2 data show that stem cell mobilization with Pegfilgrastim in children when performed during primary or without previous long lasting chemotherapy seems to produce earlier CD34+ peaks and better CD34+ yields than in Group 1. CD34+ cell mobilization with Pegfilgrastim in Group 3-patients with previous long lasting chemotherapy was possible. Pediatr Blood Cancer 2010;54:134-137. (C) 2009 Wiley-Liss, Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Child -
- Child, Preschool -
- Female -
- Granulocyte Colony-Stimulating Factor - therapeutic use
- Hematopoietic Stem Cell Mobilization -
- Humans -
- Male -
- Neoplasm Recurrence, Local - diagnosis
- Neoplasms - diagnosis
- Neutropenia - drug therapy
- Peripheral Blood Stem Cell Transplantation -
- Prognosis -
- Prospective Studies -
- Radiotherapy Dosage -
- Recombinant Proteins -
- Survival Rate -
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- CD34+cell
- children
- malignancies
- pegfilgrastim
- peripheral stem cell collection